MOUNTAIN VIEW, Calif., April 22, 2013 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced today the completion of its follow-on offering of 5,000,000 shares of common stock. ChemoCentryx also announced today that the underwriters of its follow-on offering exercised their over-allotment option in full and purchased an additional 750,000 shares of common stock today. All such shares were sold by ChemoCentryx at the follow-on offering price of $12.00 per share. The net proceeds to ChemoCentryx from this offering are approximately $64.4 million, after deducting underwriter discounts and commissions and estimated offering costs.
J. P. Morgan Securities LLC and Goldman, Sachs & Co. are acting as joint book-running managers for the offering, and Cowen and Company, LLC and Stifel, Nicolaus & Company, Incorporated are acting as co-managers for the offering.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on April 3, 2013. This offering is being made only by means of a prospectus supplement and the accompanying prospectus, copies of which may be obtained from J. P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717 or by calling toll-free (866) 803-9204 or from Goldman, Sachs & Co., Prospectus Department, 200 West Street, New York, NY, 10282, or by calling (866) 471-2526, or by e-mailing firstname.lastname@example.org.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds.
ChemoCentryx cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "may," "could," "will," "would," "should," "expect," "plan," "anticipate," "believe," "estimate," "intend," "predict," "seek," "contemplate," "potential" or "continue" or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. The inclusion of forward-looking statements should not be regarded as a representation by ChemoCentryx that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risks and uncertainties inherent in the ChemoCentryx business and other risks described in the Company's filings with the Securities and Exchange Commission ("SEC"). You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and ChemoCentryx undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in ChemoCentryx's periodic reports filed with the SEC, including ChemoCentryx's Annual Report on Form 10-K for the year ended December 31, 2012, which is available from the SEC's website (www.sec.gov). All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
CCXI - G
Source: ChemoCentryx, Inc.
CONTACT: ChemoCentryx, Inc. Susan M. Kanaya Senior Vice President, Finance and Chief Financial Officer; or Markus J. Cappel, PhD Chief Business Officer email@example.com (650) 210-2900 Burns McClellan Caitlyn Murphy firstname.lastname@example.org (212) 213-0006